Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy


Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and programmed cell death (PD)-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies have demonstrated survival benefits in numerous cancers, including melanoma and non… (More)
DOI: 10.3389/fimmu.2018.00014


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.